TAO Synergies Inc.
TAOX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TAOX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TAOX
TAO Synergies Inc. (TAOX) is a clinical-stage biotechnology company developing Bryostatin-1 for neurodegenerative diseases, with a history of negative cash flows from operations and reliance on digital assets and equity financing to support operations.
Key risk: Capital needs for clinical trials
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for TAO Synergies Inc..
TAO Synergies Inc. (TAOX) is a clinical-stage biotechnology company developing Bryostatin-1 for neurodegenerative diseases, with a history of negative cash flows from operations and reliance on digital assets and equity financing to support operations.
- Cash and equivalents of $2.4M as of 2026-06-30, with working capital of $19.6M as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Total revenue of $0.1M and net loss of -$9.3M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $21.1M as of 2026-06-30 [sec].
- Company expects current cash, cash equivalents, and digital assets of approximately $18.8M to support operations for at least 12 months from August 2026 [sec_mda · as of 2026-08-13].
- Since inception, the company has incurred negative cash flows from operations and expects to continue incurring losses over the next several years [sec_mda · as of 2026-08-13].
What works
- Working capital increased by $5.6M from December 2025 to March 2026, driven by digital assets and warrant issuances [sec_mda · as of 2026-05-13].
- Company has sufficient liquidity (cash, equivalents, and digital assets) to fund projected operations for at least 12 months from August 2026 [sec_mda · as of 2026-08-13].
- Digital assets (e.g., Tao tokens) contributed approximately $7.2M to working capital as of March 2026 [sec_mda · as of 2026-05-13].
What to weigh
- Negative cash flows from operations since inception, with net loss of $9.3M for the six months ended June 30, 2026 [sec].
- Working capital decreased by $4.0M from December 2025 to June 2026, primarily due to operating expenses and digital asset declines [sec_mda · as of 2026-08-13].
- Company requires additional capital to complete clinical trials and may face dilutive equity financing or unfavorable terms [sec_mda · as of 2026-08-13].
- Reliance on digital assets (e.g., Tao tokens) introduces volatility and liquidity risk [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Risks & what to watch (4)›
Key risks
- Capital needs for clinical trials — Company expects to require additional capital to initiate and complete AD clinical trials; funding may not be available on acceptable terms [sec_mda · as of 2026-08-13].
- Digital asset volatility — Working capital and liquidity are partly dependent on digital assets (e.g., Tao tokens), which are subject to price fluctuations [sec_mda · as of 2026-08-13].
- Dilutive equity financing — Any additional equity financing would likely be significantly dilutive to current stockholders [sec_mda · as of 2026-08-13].
- Operating losses continue — Company expects to continue incurring losses and negative cash flows from operations over the next several years [sec_mda · as of 2026-08-13].
What to watch
- Progress of Bryostatin-1 clinical trials for neurodegenerative diseases [sec_mda · as of 2026-08-13].
- Changes in digital asset holdings and their impact on working capital [sec_mda · as of 2026-08-13].
- Ability to secure additional financing (equity, debt, or partnerships) on favorable terms [sec_mda · as of 2026-08-13].
- Quarterly financial results and cash burn rate [sec].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run TAO Synergies Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TAO Synergies Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
26.9 months
D/E 0.30 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$2.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 158,738 | $903K |
| renaissance technologies llc | 101,800 | $579K |
| geode capital management, llc | 88,644 | $505K |
| vanguard fiduciary trust co | 45,432 | $259K |
| morgan stanley | 24,359 | $139K |
| blackrock, inc. | 19,753 | $112K |
| state street corp | 19,300 | $110K |
| dimensional fund advisors lp | 12,619 | $72K |
| northern trust corp | 12,126 | $69K |
| ubs group ag | 10,750 | $61K |
Showing top 10 of 24 institutional holders of TAO Synergies Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 8.6%
- Days to cover
- 3.3
- Shares short
- 627,443
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TAOX short interestGovernance
Frequently asked questions
What is the AI investment thesis for TAO Synergies Inc.?
TAO Synergies Inc. (TAOX) is a clinical-stage biotechnology company developing Bryostatin-1 for neurodegenerative diseases, with a history of negative cash flows from operations and reliance on digital assets and equity financing to support operations.
What is TAO Synergies Inc.'s lead drug candidate?
TAO Synergies Inc.'s most advanced tracked candidate is bryostatin-1 (Phase 1) for Multiple Sclerosis.
Who is the CEO of TAO Synergies Inc.?
Parkfield Funding is the chief executive officer of TAO Synergies Inc. (TAOX).
Where is TAO Synergies Inc. headquartered?
TAO Synergies Inc. (TAOX) is headquartered in New York, NY, United States.
What therapeutic areas does TAO Synergies Inc. focus on?
TAO Synergies Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.